A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Enrolling By Invitation. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- NON RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 116
- Population
- ALL
- Duration
- 2021-12-20 to 2031-07-01
- Intervention
- Standard of Care; Ranibizumab
- Comparator
- Not reported
- Outcomes measured
- Incidences of ocular Adverse Events and any Serious Adverse Events — 5 years inclusive of parent study; Incidences of non-ocular Adverse Events and any Adverse Events of Special Interest — 5 years inclusive of parent study; Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in BCVA based on ETDRS score i…; Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in CRT as measured by SD-OCT i…; Mean number of supplemental anti-VEGF injections through years 2, 3, 4 and 5 — 5 years inclusive of parent study; Mean number of supplemental anti-VEGF injections in years 2, 3, 4, and 5 — 5 years inclusive of parent study; Mean supplemental anti-VEGF injection annualized rate through years 2, 3, 4, and 5 — 5 years inclusive of parent study; Mean supplemental anti-VEGF injection annualized rate in years 2, 3, 4, and 5 — 5 years inclusive of parent study; Mean number of retina specialist visits attended for nAMD through years 2, 3, 4, and 5 — 5 years inclusive of parent st…; Mean number of retina specialist visits attended for nAMD in years 2, 3, 4, and 5 — 5 years inclusive of parent study
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.